Stanford University
Showing 121-134 of 134 Results
-
Roxanna Van Norman
Sr. Marketing Manager, Cardiothoracic Surgery
Current Role at StanfordSr. Marketing Manager, Stanford University School of Medicine, Department of Cardiothoracic Surgery
-
Hanjay Wang
Resident in Cardiothoracic Surgery - Thoracic Surgery
Affiliate, Department FundsCurrent Research and Scholarly InterestsPrecision surgery: patient-specific bypass grafting and valve repair strategies
Autonomous robotic surgery
Photosynthetic therapies to circumvent myocardial ischemia
Collateral artery formation as protection against myocardial infarction
Angiogenesis and myocardial regeneration to prevent heart failure
Tissue engineering to limit ventricular remodeling
Understanding the biomechanics of injured and failing hearts -
Joseph Woo, MD, FACS, FACC, FAHA
Norman E. Shumway Professor, Professor of Cardiothoracic Surgery and, by courtesy, of Bioengineering
BioDr. Woo is a nationally recognized surgeon, innovator, researcher, and educator in cardiothoracic surgery.
He chairs the Stanford Health Cardiothoracic Surgery Department. He is the Norman E. Shumway Professor of Cardiothoracic Surgery and holds a courtesy appointment in the Department of Bioengineering.
Dr. Woo is a board-certified, fellowship-trained heart surgeon with an active clinical practice of more than 300 pump cases per year. He focuses on complex mitral and aortic valve repair, thoracic aortic surgery, cardiopulmonary transplantation, and minimally invasive surgery.
He has advanced these fields by developing innovative surgical procedures. He serves as principal investigator on two studies funded by National Institutes of Health (NIH) grants. One explores stem cells, angiogenesis, tissue engineering, and valvular biomechanics. Dr. Woo has received NIH funding for this study continuously since 2004.
He has served as primary investigator for clinical device trials. He also has been the primary investigator for translational scientific clinical trials entailing administration of stem cells during coronary artery bypass grafting and left ventricular arterial device (LVAD) implantation.
Dr. Woo has co-authored more than 400 articles in peer-reviewed publications.
Dr. Woo serves on the board of directors of the American Association for Thoracic Surgery (AATS). He is the president of the AATS Cardiac Surgery Biology Club. He is a fellow of the American College of Surgeons, American College of Cardiology, and American Heart Association. He serves on the leadership committee of the American Heart Association’s Council on Cardiovascular Surgery and Anesthesia.
He is a member of the Society of Thoracic Surgeons, International Society for Minimally Invasive Cardiac Surgery, International Society for Heart & Lung Transplantation, International Society for Heart Research, and other professional societies. -
Shin Yajima
Postdoctoral Scholar, Cardiothoracic Surgery
BioI am a board-certified cardiothoracic surgeon in Japan. Throughout my clinical experience and research, I realized that insufficient myocardial blood flow had little impact on myocardial functional recovery because percutaneous coronary intervention or coronary artery bypass grafting (CABG) could approach and supply blood flow to the superficial large coronary arteries, but not to intramyocardial microvascular arteries, especially where microvasculature was scarce or absent. Moreover, myocardial ischemia-reperfusion (I/R) impaired cardiac functional recovery in ischemic hearts, including transplanted hearts. As a result, my research interests include myocardial microvascular dysfunction and myocardial I/R injury.
During my Ph.D. studies in cardiovascular surgery, I focused on a prostacyclin analog that inhibits thromboxane A2 synthase and promotes angiogenesis and restores myocardial blood flow via proangiogenic and vasodilatory effects. Direct epicardial placement of a microform of this compound in a porcine ischemia cardiomyopathy model resulted in enhanced myocardial angiogenesis and recovery of myocardial function. Then, I developed nanoparticles (NPs) that contained this compound, which I applied to a rat ischemia myocardial reperfusion model with intravenous injection to demonstrate attenuated myocardial I/R injury with selective accumulation in the ischemic myocardium, better-preserved capillary networks, better-preserved myocardial blood flow, and a smaller infarct size. Using induced pluripotent stem cells (iPSCs) and adipose-derived mesenchymal stem cells, I have also worked on tissue engineering for myocardial regeneration. With direct implantation of cardiomyocyte sheets derived from human iPSCs onto ischemic myocardial tissue, we elucidated myocardial regeneration through thickened myocardial tissue, proangiogenic effects, improved cardiac performance, and reduced left ventricular remodeling in both small and large animals. These works have already been published (representative examples are provided below), and I have received a number of academic honors and research grants (ongoing research support; Japan Heart Foundation/Bayer Research Grant Abroad, 01/01/2022 - 12/31/2022).
My career goal is to attain leadership in academic cardiovascular surgery. During my postdoctoral fellowship, I intend to create novel therapeutic methods to improve the outcomes of ischemic heart disease through engineering analysis and the development of innovative solutions. My mentor, Dr. Woo, is a distinguished mentor with a stellar reputation for training academic surgeons, and Stanford University provides extraordinary research resources. I feel extremely fortunate to have such an ideal environment in which to carry out this project and continue bioengineering's advancement of cardiothoracic surgery. -
Cyril Zakka, MD
Postdoctoral Scholar, Cardiothoracic Surgery
Current Research and Scholarly InterestsCyril Zakka's research is primarily focused on building unsupervised deep learning representation learners for use in a variety of medical tasks, such as medical imaging (e.g. cardiac MRIs and echocardiograms), and autonomous robotic surgical systems. He is particularly interested in developing algorithms that augment operating physicians' capabilities in order to improve on patient outcomes post-operatively.
